The decoding of the human genome nearly 20 years ago heralded the coming of the genomic revolution. Indeed, the last decades have seen the advent of Precision Medicine: the development of effective treatments that are based on the knowledge of the genetic anomalies linked to a specific disease.
We believe in empowering the patient and healthcare professional and that’s why we are focused on making the latest genetic tests accessible to everybody
For patients to benefit from such advances, they need broad access to the right test, at the right time. Unfortunately, due to their complexity and cost, these genetic can be performed only in a handful of specialized laboratories.
With BioCeryx’s molecular diagnostic platform, the company aims to democratize precision medicine by enabling any lab to offer high complexity tests with maximal quality and efficiency. BioCeryx is effectively miniaturizing a lab comprised of dozens of instruments into a single piece of equipment, and a laboratory process that would take days and many hours of skilled labor into a fully automated microfluidic card. This will allow any lab to perform highly complex tests easily, cost effectively and quickly. “Nowadays, many laboratories need to perform tests in large batches to cut down costs. However, a local hospital using our platform can run precision medicine tests on demand and provide actionable results sooner. We can’t afford to have a world where genetic testing is for the haves and not for the have nots. We believe in putting science and technology to the service of everybody and that’s why we are focused on making the latest genetic tests accessible,” explains Marc Montserrat, VP of Commercial Operations of BioCeryx.
With the expertise of the industry veterans along with a talented technical team, BioCeryx focuses on fulfilling the massive need for distributed precision medicine diagnostics and making sure that these advances in genomics reach everyone in need. BioCeryx will initially launch in Europe with a focus on women’s health and is actively looking into additional indications such as oncology and infectious diseases. For the future, BioCeryx looks forward to expanding the team considerably throughout 2019 to build manufacturing and sales and marketing capabilities. “As the field of genomic and genetic testing continues to grow, we look forward to partnering with other companies to develop applications on our platform so that we can enable a whole host of tests and make them accessible to patients,” concludes Balog.